NCT03453255 is a Phase 1, PHASE2 clinical trial of Chemotherapy in Chemotherapy, sponsored by Chinese PLA General Hospital.

Who is sponsoring NCT03453255?

NCT03453255 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT03453255?

Interventions in NCT03453255: Chemotherapy.

What condition does NCT03453255 study?

NCT03453255 studies Chemotherapy.

Is NCT03453255 still recruiting?

NCT03453255 is currently status unknown. Last updated 5 March 2018.

Last reviewed 2018-03-05 · How we verify

NCT03453255

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCHA as Postremission Therapy for AML With t(8;21)

Status unknown Phase 1, PHASE2 Last updated 5 March 2018

What this trial tests

Phase 1, PHASE2 trial testing Chemotherapy in Chemotherapy in 120 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 January 2018
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Chemotherapy (chemotherapy) — full drug profile →

Conditions studied

Chemotherapy — all drugs for Chemotherapy →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 14 to 65, any sex, with Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute myelocytic leukemia ( AML) is a highly heterogeneous group of malignant hematopathy. Chromosomal translocation with t (8; 21) (q22; q22) , about 10 \~ 15% incidence in AML and 40% incidence in the AML-M2 type of leukemia, is a karyotype that is considered to have a good prognosis. The National Comprehensive Cancer Network (NCCN) guidelines recommend that high-dose Ara-c regimens may benefit for patients, but with 30 to 40% relapse and serious risks on myelosuppression, infection and bleeding in high-dose Ara-c consolidation chemotherapy and more than 70% recurrence rate with （tyrosine kinase）KIT mutation. So the exploration of a relatively safe and efficient consolidation therapy is one of the difficult problems to be solved in the treatment of mitigatory t (8; 21) AML.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells.
Costa RGA, Silva SLR, Dias IRSB, Oliveira MS, et al · · 2023 · cited 16× · PMID 37031536 · DOI 10.1016/j.redox.2023.102692
Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia.
Xu H, Wen Y, Jin R, Chen H. · · 2022 · cited 12× · PMID 36147798 · DOI 10.3389/fped.2022.975819
Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.
Ernst P, Heidel FH. · · 2021 · cited 8× · PMID 33557090 · DOI 10.3390/cancers13040612

Verify or expand the search:

Other trials of Chemotherapy

Trials testing the same drug.

NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting

Other recruiting trials for Chemotherapy

Currently open trials in the same condition.

NCT07435597 — Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients · NA · recruiting
NCT07218874 — Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application · NA · recruiting
NCT07339488 — Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal · Phase 2 · active not recruiting
NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting
NCT06999616 — Physical Activity in Cancer Patients in an Oncology Day Clinic - Implementing a Person-centered Program Led by Nurses · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03453255 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 5 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03453255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing